1 **BRIEF REPORT:** Impact of age and SARS-CoV-2 breakthrough infection on humoral immune

2 responses after three doses of COVID-19 mRNA vaccine

3

- Francis Mwimanzi¹, Hope R. Lapointe², Peter K. Cheung^{1,2}, Yurou Sang¹, Fatima Yaseen¹, Rebecca Kalikawe¹, Sneha Datwani¹, Laura Burns³, Landon Young³, Victor Leung^{4,5}, Siobhan Ennis¹, Chanson J. Brumme^{2,4}, Julio S.G. Montaner^{2,4}, Natalie Prystajecky^{5,6}, Christopher F. Lowe^{3,5}, Mari L. DeMarco^{3,5}, Daniel T. Holmes^{3,5}, Janet Simons^{3,5}, Masahiro Niikura¹, Marc G. Romney^{3,5,*}, Zabrina L. Brumme^{1,2,*}, Mark A. Brockman^{1,2,*} 4 5
- 6
- 7
- 8
- 9
- 10 1. Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6, Canada;
- 11 2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, V6Z 1Y6, Canada;
- 3. Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, V6Z 1Y6, Canada; 12
- 13 4. Department of Medicine, University of British Columbia, Vancouver, V6T 1Z3, Canada;
- 14 5. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, 15 V6T 1Z7, Canada
- 6. British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, V5Z 4R4, 16 17 Canada
- 18
- 19 *MAB, MGR and ZLB contributed equally
- 20

21 **Corresponding Author Contact Information:**

- 22 Mark A. Brockman, Ph.D.
- 23 Professor, Faculty of Health Sciences, Simon Fraser University
- 24 8888 University Drive, Burnaby, BC, Canada, V5A 1S6
- 25 Tel: 778 782-3341; Fax: 778-782-5927;
- 26 email: mark brockman@sfu.ca
- 27
- 28

29 ABSTRACT

30	Longitudinal	immune resp	onse data	following	three-dose	COVID-19	mRNA	vaccination	remain
	0			0					

- 31 limited, particularly in older adults and those experiencing their first SARS-CoV-2 infection. We
- 32 quantified wild-type- and Omicron-specific antibody concentrations and virus neutralization activity up
- to six months post-third-dose in COVID-19-naive adults aged 24-98 years. Among participants who
- remained COVID-19-naïve, antibody concentrations were comparable between age groups over time.
- 35 Omicron-specific neutralization declined more rapidly in older adults, and at six months was
- 36 undetectable in 56% and 96% of COVID-19-naive younger and older adults, respectively. Post-vaccine
- 37 SARS-CoV-2 breakthrough infections increased wild-type- and Omicron-specific responses above
- 38 three-dose vaccination alone, illustrating beneficial hybrid immunity.

- 40 Key words: COVID-19, mRNA vaccine, humoral immunity, hybrid immunity, post-vaccination
- 41 infection, older adults, binding antibodies, viral neutralization, Omicron

42 INTRODUCTION

43	Third COVID-19 mRNA vaccine doses, provided to immunocompromised and clinically-
44	vulnerable individuals to complete their initial vaccine series [1-3] or as "booster" doses in the general
45	population to offset natural antibody decline and augment responses against the more immune-evasive
46	Omicron variants [4], enhanced protection against severe disease [1, 5, 6] but did not prevent
47	widespread Omicron-driven infections [7, 8]. Few studies have assessed post-third-dose immune
48	response durability across the adult age spectrum, nor compared vaccine-induced to "hybrid" antibody
49	responses elicited by three-dose vaccination followed by SARS-CoV-2 breakthrough infection,
50	information that could help inform the design and delivery of future vaccine boosters.
51	In a prior study, we reported that older adults mounted weaker antibody responses than
52	younger adults after two vaccine doses, but equivalent initial responses after three doses [9]. Here, we
53	longitudinally examine wild-type- and Omicron-specific antibody concentration and function up to six
54	months post-third-dose in 116 individuals who remained COVID-19-naïve until at least one month
55	post-third-dose. One-third of participants experienced SARS-CoV-2 (presumably Omicron) infection
56	during follow-up, allowing us to additionally compare vaccine-induced and "hybrid" immune responses
57	[10].
58	

59 METHODS

Participants. Our British Columbia (BC), Canada, cohort has been described previously [9]. Here, we
studied the subset of 69 healthcare workers (HCW) and 47 older adults (OA) who remained COVID-19

- 62 naive until at least one month after their third COVID-19 mRNA vaccine dose (Table S1). Post-
- 63 vaccine SARS-CoV-2 infections were detected by the development of serum antibodies against

Nucleocapsid (N) using the Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics), combined with
diagnostic (PCR- and/or rapid-antigen-test-based) information.

66

Ethics approval. Written informed consent was obtained from all participants or their authorized
decision makers. This study was approved by the University of British Columbia/Providence Health
Care and Simon Fraser University Research Ethics Boards.

70

Assays. We quantified IgG-binding antibodies in serum against the SARS-CoV-2 Spike Receptor 71 72 Binding Domain (RBD) using the V-plex SARS-CoV-2 (IgG) ELISA kit (Panel 22; Meso Scale 73 Diagnostics), which features WT (Wuhan) and Omicron (BA.1) RBD antigens, on a Meso QuickPlex 74 SQ120 instrument. Serum was diluted 1:10000, with results reported in Arbitrary Units (U)/mL. We 75 assessed surrogate virus neutralization activity [11] in serum by competition ELISA using the same kit 76 (Panel 22; V-plex SARS-CoV-2 [ACE2]) to measure blockade of the RBD-ACE2 receptor interaction. 77 Sera were diluted 1:40 and results reported as % ACE2 displacement. A subset of specimens was also 78 tested for IgG-binding antibodies and ACE2 displacement using V-plex assays that featured Wuhan, 79 BA.1, BA.2 and BA.3 Spike antigens (Panel 25). Virus neutralizing activity in plasma was examined 80 using live WT (USA-WA1/2020; BEI Resources) and Omicron BA.1 (GISAID EPI_ISL_9805779) 81 viruses on VeroE6-TMPRSS2 (JCRB-1819) target cells [9]. Virus stocks were diluted to 50 82 $TCID_{50}/200 \ \mu l$ in the presence of serial 2-fold plasma dilutions (1/20 to 1/2560) and added to target 83 cells in triplicate. Viral cytopathic effects (CPE) were recorded three days post-infection. 84 Neutralization was reported as the highest reciprocal dilution able to prevent CPE in all three wells. 85 Partial or no neutralization at 1/20 dilution was considered below the limit of quantification (BLOQ). 86

87 **RESULTS**

88 Participant characteristics

89	HCW and OA were a median of 40 and 78 years old, respectively (range 24-98 years old), and
90	predominantly female (Table S1). OA were predominantly of white ethnicity (74%, compared to 46%
91	of HCW) and had more chronic health conditions (median of 1, interquartile range [IQR] 0-2 in OA
92	versus 0 [IQR 0-1] in HCW). Most participants (97% of HCW and 81% of OA) initially received two
93	BNT162b2 doses. Third doses were predominantly mRNA-1273 (52% of HCW and 62% of OA),
94	which were administered in an age-dependent manner per local guidelines: most OA received 100 mcg
95	whereas HCW received 50 mcg. Third doses were administered an average of ~7 months after the
96	second. During follow-up, 43% of HCW and 17% of OA experienced their first SARS-CoV-2
97	infection; based on local epidemiology most were suspected to be Omicron BA.1 or BA.2 [12].
98	
99	Binding antibodies
100	As reported previously [9, 13], anti-RBD serum IgG concentrations were lower in COVID-19-
101	naive OA compared to younger HCW after two vaccine doses, but the third dose significantly enhanced
102	these responses (Figure 1A). One month post-third dose, WT-specific anti-RBD IgG concentrations
103	were equivalent in the two groups: a median of 5.21 (IQR 5.08-5.45) \log_{10} U/mL in HCW versus 5.25
104	(IQR 4.99-5.43) in OA (p=0.7). Among COVID-19-naive participants, WT-specific IgG responses
105	declined to a median 4.95 (IQR 4.79-5.16) in HCW versus 4.96 (IQR 4.76-5.17) in OA at three months
106	
100	post-third dose (p=0.9), and to a median 4.64 (IQR 4.42-4.84) in HCW versus 4.59 (IQR 4.35-4.87) in
100	post-third dose (p=0.9), and to a median 4.64 (IQR 4.42-4.84) in HCW versus 4.59 (IQR 4.35-4.87) in OA by six months (p=0.7). By six months, IgG concentrations in COVID-19-naive HCW had declined
100 107 108	post-third dose (p=0.9), and to a median 4.64 (IQR 4.42-4.84) in HCW versus 4.59 (IQR 4.35-4.87) in OA by six months (p=0.7). By six months, IgG concentrations in COVID-19-naive HCW had declined to below post-second-dose levels (p<0.0001) while in OA they had declined to comparable levels as

to be a median 73 (IQR 53-101) days in COVID-19-naive HCW versus 69 (IQR 54-91) days in OA (p=0.8; Figures 1B, 1C).

112	By contrast, individuals who experienced SARS-CoV-2 infection during follow-up exhibited
113	markedly higher IgG concentrations than their COVID-19-naive counterparts at three and six months
114	post-third dose (both p<0.0001; Figure 1A). Notably, at six months, IgG concentrations in "hybrid
115	immunity" participants were a median 5.50 (IQR 5.17-5.79) \log_{10} U/mL, which was significantly
116	higher than their responses induced by three vaccine doses alone (p=0.0005). Individual-level
117	longitudinal responses are detailed in Figure S1. Identical trends were observed for Omicron (BA.1)-
118	specific IgG concentrations, though these were on average $\sim 0.6 \log_{10}$ lower than WT-specific responses
119	at all time points (Figure 1A; Figure S1). In COVID-19-naive individuals, Omicron-specific IgG half-
120	lives were similar to WT-specific ones and were comparable between OA (median 75 days [IQR 58-
121	93]) and HCW (78 [IQR 64-94]) (p=0.5; Figure S2).
122	

123 ACE2 displacement

124 While ACE2 displacement activities against WT and Omicron (BA.1) variants were lower in 125 COVID-19-naive OA compared to HCW following two vaccine doses, these responses increased to 126 equivalence one month post-third dose: a median 98.7% (IQR 96.3-99.3) in HCW versus 99.3% (IQR 127 96.0-99.7) OA for WT (p=0.12), and a median of 62.5% (IQR 46.2-75.5) in HCW versus 66.2% (IQR 44.6-79.3) in OA for Omicron BA.1 (p=0.4) (Figure 2A). Among COVID-19-naive participants, WT-128 129 specific ACE2 displacement activities declined similarly in both groups, to a median 98.0% (IQR 93.7-130 99.3) in HCW versus 98.3% (IQR 91.7-99.5) in OA at three months post-third dose (p=0.9), and a median 92.8% (IQR 80.0-99.9) in HCW versus 91.4% (IQR 72.3-97.1) in OA at six months (p=0.4). 131 132 Omicron-specific ACE2 displacement declined slightly faster in OA, particularly between 3-6 months,

133	to a median 48.6% (IQR 20.5-73.8) in HCW versus 47.6% (IQR 14.2-71.7) in OA at three months
134	post-third dose (p=0.4), and a median 43.3% (IQR 13.4-62.2) in HCW versus 20.7% (IQR 5.6-32.3) in
135	OA at six months (p=0.04). By six months post-third dose, WT- and Omicron-specific ACE2
136	displacement activities in COVID-19-naive HCW had declined to below post-second-dose levels
137	(p<0.0001 and p=0.02 respectively), while in COVID-19-naive OA they had declined to comparable
138	levels as achieved after two doses (p=0.6 and p=0.4, respectively). By contrast, post-vaccination
139	SARS-CoV-2 infection induced a strong functional boost: at six months, ACE2 displacement activities
140	against both WT and Omicron in the hybrid immunity group significantly exceeded those originally
141	induced by three vaccine doses alone (both comparisons p<0.0001; Figure 2A; also see Figure S1).
142	Omicron-specific ACE2 displacement activities for example rose to a median 95.9% (IQR 90.0-97.8)
143	in the hybrid group at six months.

144

145 Virus neutralization

146 Live virus neutralization activity was weaker in OA versus younger HCW following two 147 vaccine doses, but it reached equivalence one month post-third-dose when reciprocal plasma dilutions 148 required to neutralize WT were a median 320 (IQR 160-320) in HCW versus a median 320 (IQR 80-149 640) in OA (p=0.9), while those required to neutralize Omicron (BA.1) were a median 40 (IQR 20-80) 150 in both groups (p=0.8) (Figure 2B). Among COVID-19-naive participants, WT neutralization declined 151 relatively similarly in both groups, to median reciprocal dilutions of 80 (IQR 80-160) in HCW versus 152 80 (IQR 40-160) in OA at three months post-third dose (p=0.03), and a median 40 (IQR 20-80) in 153 HCW versus 20 (IQR 20-80) in OA at six months (p=0.3). By contrast, Omicron-specific neutralization 154 declined faster in OA, to median reciprocal dilutions of 40 (IQR 20-80) in HCW versus BLOQ (IQR 155 BLOQ-BLOQ) in OA at three months (p=0.004), and BLOQ (IQR BLOQ-20) in HCW versus BLOQ

156	[IQR BLOQ-BLOQ] in HCW at six months (p=0.003). At six months, neutralization function in
157	COVID-19-naive participants had declined to below post-second-dose levels (e.g. WT-specific p-
158	values <0.05; Figure 2B), and Omicron-specific-neutralization was BLOQ in 56% and 96% of
159	COVID-19-naive HCW and OA, respectively. By contrast, post-vaccination SARS-CoV-2 infection
160	induced a strong neutralization boost: at six months, WT- and Omicron-specific neutralization
161	activities in the hybrid group significantly exceeded those induced by three vaccine doses alone (all
162	$p \le 0.002$; Figure 2B; also see Figure S2). Omicron-specific neutralization for example was a median
163	reciprocal dilution of 80 (IQR 80-160) in the hybrid group at six months (Figure 2B).
164	
165	Responses to other Omicron variants

166 To estimate immune responses to other Omicron variants, we quantified anti-Spike IgG levels 167 and ACE2 displacement activities specific to WT, BA.1, BA.2 and BA.3 variants in 25 participants one 168 month post-third-dose. Compared to WT-specific responses, anti-Spike IgG concentrations were on 169 average ~ $0.4 \log_{10}$ lower for Omicron variants, while ACE2 displacement activities were on average at 170 least 30% lower for Omicron variants (all p<0.0001; Figure S3). BA.2-specific anti-Spike IgG 171 concentrations were comparable to BA.1 (p=0.2), while BA.2-specific ACE2 displacement activities 172 were marginally lower (p=0.01). BA.3-specific anti-Spike IgG concentrations and ACE2 displacement 173 activities were significantly lower than BA.1 (both p<0.0001), though the magnitude of these 174 differences was modest (e.g. median IgG was 5.42 log₁₀ for BA.1 versus 5.35 log₁₀ for BA.3). The 175 correlation between anti-Spike and anti-RBD measurements for the WT and BA.1 antigens was strong 176 (Spearman's $\rho \ge 0.86$, p<0.0001; Figure S3).

177

179 **DISCUSSION**

180 A third COVID-19 mRNA vaccine dose significantly enhances antibody responses in SARS-181 CoV-2-naive individuals, including to the Omicron variant, and particularly in older adults. At one, 182 three and six months post-third-dose, WT- and Omicron-specific anti-RBD binding IgG concentrations 183 were of comparable magnitude and declined at similar rates in older and younger adults, though 184 Omicron-specific responses were consistently $\sim 0.6 \log_{10}$ lower than WT. Longitudinal WT-specific 185 ACE2 displacement and neutralization activities were also similar between groups, but older adults 186 displayed lower Omicron-specific ACE2 displacement activity at six months post-third dose, and lower 187 Omicron-specific neutralization at both three and six months post-third dose compared to younger 188 adults. This is consistent with impaired Omicron-specific antibody function in older adults that is only 189 revealed as antibody concentrations decline. Notably, by six months post-third-dose, antibody 190 responses in COVID-19-naive participants of all ages had declined markedly to or below those initially 191 elicited by two-dose vaccination, with anti-Omicron neutralization below the limit of quantification in 192 56% of younger and 96% of older adults by this time (79% of OA were already BLOQ at 3 months). 193 By contrast, both younger and older adults who experienced their first SARS-CoV-2 infection 194 (presumably Omicron BA.1 or BA.2 [12]) after three-dose vaccination demonstrated superior binding 195 and functional humoral responses to those induced by triple-vaccination alone. This is consistent with 196 other studies of hybrid immunity [10, 14, 15] and suggests that a post-third-dose infection may provide 197 prolonged immune protection. The observation that immune enhancement was most pronounced for 198 Omicron-specific responses (e.g. see Figure 2A), and extended to antibody function, is likely 199 attributable to exposure to Omicron Spike. If so, heterologous booster vaccination with variant Spike 200 antigens may offer similar benefits.

201	Though these findings further underscore the immune benefits of third/booster doses in all ages,
202	they suggest that COVID-19-naive individuals, particularly older adults, may benefit from an
203	additional booster dose by six months. By contrast, individuals who contracted their first SARS-CoV-2
204	infection following three-dose vaccination may benefit less from a booster within this time frame.
205	Exposure to Omicron-like antigens, whether from infection or a multivalent vaccine that includes
206	variant Spike/RBDs, will likely elicit superior immune responses against circulating variants compared
207	to immunization with existing, WT-only vaccines. Additional studies are needed to assess the
208	durability of hybrid immune responses and to evaluate cross-reactivity against emerging viral variants.
209	
210	ACKNOWLEDGEMENTS
211	We thank the leadership and staff of Providence Health Care, including long-term care and
212	assisted living residences, for their support of this study. We thank the phlebotomists and laboratory
213	staff at St. Paul's Hospital, the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research
214	and Innovation Centre, and Simon Fraser University for assistance. Above all, we thank the
215	participants, without whom this study would not have been possible.
216	
217	FUNDING
218	This work was supported by the Public Health Agency of Canada through a COVID-19
219	Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120 to MGR, ZLB, MAB).
220	Additional funding was received from the Canadian Institutes for Health Research (GA2-177713 and
221	the Coronavirus Variants Rapid Response Network (FRN-175622) to MAB), the Canada Foundation
222	for Innovation through Exceptional Opportunities Fund – COVID-19 awards (to MAB, MD, MN,
223	ZLB). FM is supported by a fellowship from the CIHR Canadian HIV Trials Network. FY was

supported by an SFU Undergraduate Research Award. MLD and ZLB hold Scholar Awards from theMichael Smith Foundation for Health Research.

226

227 FIGURE LEGENDS

Figure 1. Serum anti-RBD IgG concentrations following three-dose COVID-19 vaccination. Panel

A: Longitudinal serum anti-RBD IgG concentrations specific to WT (left side) and Omicron BA.1

230 (right side) in COVID-19-naive health care workers (HCW; blue circles) and older adults (OA; orange

circles). Any participant who experienced a SARS-CoV-2 breakthrough infection between 1-3 or 3-6

232 months post-third-dose was reclassified into the "HYBRID" group at their following study visit (black

233 circles). At six months post-third-dose, the black symbols in the HYBRID group denote recent

infections occurring between 3-6 months, while the grey symbols denote participants who had been

235 infected between 1-3 months. Red bars indicate median and IQR. Comparisons between independent

236 groups were performed using the Mann-Whitney U-test; longitudinal paired comparisons were

237 performed using the Wilcoxon matched pairs test. P-values are not corrected for multiple comparisons.

238 *Panel B:* Temporal declines in anti-RBD IgG responses following three-dose vaccination in HCW

(blue) and OA (orange) who remained COVID-19-naive during follow-up, and who completed all three

240 post-third dose visits. *Panel C*: Estimated IgG half-lives following three-dose vaccination, calculated

by fitting an exponential curve to each participant's data in panel B. Red bars and whiskers represent

the median and IQR. P-values were computed using the Mann-Whitney U-test.

243

Figure 2. Functional humoral responses following three-dose COVID-19 vaccination. Panel A:

Same as Figure 1A, but for ACE2 displacement activity, where results are reported in terms of %

ACE2 displacement. Panel B: same as Figure 1A, but for virus neutralization activity, defined as the

247	lowest reciprocal plasma dilution at which neutralization was observed in all wells of a triplicate assay.
248	Serial two-fold dilutions of 1/20 (lower limit of quantification; LLOQ) to 1/2560 (upper limit of
249	quantification; ULOQ) were tested. Plasma samples showing neutralization in fewer than three wells at
250	a 1/20 dilution are displayed as a reciprocal dilution of "10" and were reported as below limit of
251	quantification (BLOQ) in the text. Note that many datapoints are superimposed.
252	
253	Supplemental Figures
254	Figure S1: Longitudinal humoral responses to WT and Omicron variants following three-dose
255	COVID-19 vaccination. Panel A: Longitudinal serum anti-RBD IgG concentrations specific to WT
256	(left side) and Omicron BA.1 (right side) in health care workers (HCW; blue circles) and older adults
257	(OA; orange circles). Blue and orange symbols are jittered for visualization. Participants are stratified
258	into three groups: COVID-19-naive, SARS-CoV-2 infection between 1-3 months post-third-dose, and
259	SARS-CoV-2 infection between 3-6 months post-third-dose. P-values are computed using the
260	Wilcoxon matched pairs test and are not corrected for multiple comparisons. Horizontal red lines
261	denote the overall median response at each time point (where HCW and OA are treated as a combined
262	group). Panel B: Same as A, but for ACE2 % displacement activity in serum. Panel C: Same as A, but
263	for viral neutralization activity in plasma, defined as the lowest reciprocal plasma dilution at which
264	neutralization was observed in all triplicate assay wells. Serial two-fold dilutions of 1/20 (lower limit of
265	quantification; LLOQ) to 1/2560 (upper limit of quantification; ULOQ) were tested. Plasma samples
266	showing neutralization in fewer than three wells at a 1/20 dilution are displayed as a reciprocal dilution
267	of "10" and were reported as below limit of quantification (BLOQ) in the text. Note that many
268	datapoints are superimposed.

270 Figure S2: Omicron-specific anti-RBD IgG decline following three-dose COVID-19 vaccination.

271 Panel A: Temporal declines in Omicron (BA.1)-specific anti-RBD IgG responses following three-dose

vaccination in HCW (blue) and older adults (orange) who remained COVID-19 naive during follow-up,

and who completed all three post-third dose visits. *Panel B*: Estimated Omicron (BA.1)-specific IgG

half-lives following three COVID-19 vaccine doses, calculated by fitting an exponential curve to each

275 participant's data shown in panel B. Red bars and whiskers represent the median and IQR. P-values

276 were computed using the Mann-Whitney U-test.

277

278 Figure S3: Anti-S IgG and ACE2 displacement activities against an expanded panel of Omicron

variants. *Panel A:* Concentrations of IgG capable of binding WT, Omicron BA.1, BA.2 and BA.3

280 Spike proteins in a subset of n=25 participants measured one month post-third vaccine dose. HCW in

blue; OA in orange; dots are jittered for visualization. P-values are computed using the Wilcoxon

282 matched pairs test and are uncorrected for multiple comparisons. Horizontal red lines denote the overall

283 median response to each variant (HCW and OA are treated as a combined group). *Panel B*: same as

284 Panel A, but for ACE2% displacement activity. Panel C: Correlation between WT and Omicron BA.1-

- specific anti-Spike IgG concentrations (shown in this figure) with the original anti-RBD IgG
- 286 measurements shown in the primary analysis (in Figure 1A). *Panel D*: Correlation between WT and
- 287 Omicron BA.1-specific anti-Spike ACE2 displacement with the original anti-RBD measurements
- shown in the primary analysis.

289

291 **REFERENCES**

- Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021; 398:2093-100.
- 295 2. Moreira ED, Jr., Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19
 296 Vaccine. N Engl J Med 2022; 386:1910-21.
- 297 3. Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, et al. Antibody Titers Before and After a Third
 298 Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged >/=60 Years. JAMA 2021;
 299 326:2203-4.
- 4. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants
 BA.2.12.1, BA.4, & BA.5. Nature 2022.
- 302 5. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA Vaccine Boosters against SARS 303 CoV-2 Omicron Infection in Qatar. N Engl J Med 2022; 386:1804-16.
- 304 6. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron
 305 (B.1.1.529) Variant. N Engl J Med 2022; 386:1532-46.

7. Christensen PA, Olsen RJ, Long SW, et al. Signals of Significantly Increased Vaccine Breakthrough,
 Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease
 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in
 Houston, Texas. Am J Pathol 2022; 192:642-52.

- 8. Staerke NB, Reekie J, Nielsen H, et al. Levels of SARS-CoV-2 antibodies among fully vaccinated
 individuals with Delta or Omicron variant breakthrough infections. Nat Commun 2022; 13:4466.
- 9. Mwimanzi F, Lapointe HR, Cheung PK, et al. Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose. J Infect Dis
 2022.
- 315 10. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads
 316 to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol 2022;
 317 7:eabn8014.
- 11. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on
 antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol 2020;
 38:1073-8.
- 321 12. BC Centre for Disease Control. Weekly update on Variants of Concern. Available at:
 322 <u>http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data</u>. 2022.
- 323 13. Brockman MA, Mwimanzi F, Lapointe HR, et al. Reduced Magnitude and Durability of Humoral
 324 Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. J Infect Dis 2022;
 325 225:1129-40.

- 14. Chen Y, Tong P, Whiteman N, et al. Immune recall improves antibody durability and breadth to
 SARS-CoV-2 variants. Sci Immunol 2022:eabp8328.
- 15. Curlin ME, Bates TA, Guzman G, et al. Omicron neutralizing antibody response following booster
 vaccination compared with breakthrough infection. medRxiv 2022.



a

b

COVID-19 naive

medRxiv preprint doi: https://doi.org/10.1101/2022.08.08.22278494; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a licence to the preprint in perpetbilition of the preprint in perpetbilition of the preprint in perpetbilition of the preprint of the p



b

a

b

С





months post-3rd dose

LLOQ

6

n=20 3

Figure S2



Figure S3



Table 1: Participant characteristics

Characteristic	HCW (n=69)	Older Adults (n=47)
Sociodemographic and health variables	(1 0))	(1 1)
Age in years, median [IQR]	40 [34-51]	78 [72-83]
Female sex at birth, n (%)	53 (77%)	34 (72%)
white Ethnicity, n (%)	32 (46%)	35 (74%)
Number of chronic health conditions, median [IQR]	0 [0-1]	1 [0-2]
Vaccine details		
Initial regimen		
BNT162b2 - BNT162b2	67 (97%)	38 (81%)
mRNA-1273 - mRNA-1273	1 (1.5%)	7 (15%)
heterologous mRNA	1 (1.5%)	2 (4%)
Third dose		
BNT162b2	33 (48%)	18 (38%)
mRNA-1273	36 (52%)	29 (62%)
Date range that third doses were received	Oct 2021-Feb 2022	Oct 2021-Jan 2022
Time between second and third doses in days, median [IQR]	210 [199-232]	198 [173-216]
Specimen collection		
1 month after third dose, n (%)	68 (99%)	47 (100%)
3 months after third dose, n (%)	68 (99%)	45 (96%)
6 months after third dose, n (%)	57 (83%)	44 (94%)
Post-vaccination SARS-CoV-2 infections, n (%)	30 (43%)	8 (17%)